Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Impact · against what's priced in

The announcement of a deadline for lead plaintiff motions in a securities fraud class action is not a material catalyst for UNCY. The underlying causes—the FDA CRL and the failure to audit third-party manufacturing—are already reflected in the stock's valuation.

UNCY−0.10

No priced-in read yet